What are the criteria for evaluating innovation in biotechnology?

When it comes to evaluating innovation in biotechnology, the criteria go beyond creating something new: they measure how much an advance truly represents progress and how much it can benefit society. In the context of the EB-2 NIW, understanding this logic helps position your contributions as work of merit and national importance.

In general, the evaluation tends to revolve around a few qualitative dimensions:

• Originality and advancement: methods, processes, or products that represent a meaningful evolution beyond existing techniques.
• Efficacy and applicability: demonstrated ability to function and to be adopted in real-world problems.
• Impact: benefits to public health, industry, agriculture, or other strategic sectors.
• Recognition: publications, patents, awards, and partnerships with respected institutions that validate the contribution.

In the context of an immigration petition, these elements must be translated into evidence: it is not enough to describe the innovation; you must document its reach and how it serves a broader interest. Collaborations, funding, and third-party adoption typically strengthen that reading.

Since each case is evaluated individually by the competent authority, it is worth checking the updated requirements with USCIS and assessing your profile with a specialist before filing.

About the author

Victoria Harper

Editor-in-Chief

Meet the author

As a journalist and lead editor at Visto n’ Visa, Victoria helps ensure that immigration topics are covered in a clear, trustworthy, and easy-to-understand way. Her focus is on delivering useful, human, and relevant content for people exploring new paths abroad.